This technology uses drugs like clindamycin or terbutaline to boost the brain’s natural waste-clearing system after traumatic brain injury, speeding up recovery by enhancing fluid flow and removing harmful substances through stimulation of ependymal cilia.
Background
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide, with millions affected each year. The pathophysiology of TBI is complex, involving not only the initial mechanical insult but also a cascade of secondary injuries such as blood-brain barrier (BBB) disruption, neuroinflammation, and accumulation of neurotoxic metabolites. The brain's glymphatic system, which relies on the movement of cerebrospinal fluid (CSF) to clear waste products from neural tissue, has emerged as a critical player in maintaining brain health and facilitating recovery after injury. Ependymal cilia, which line the brain's ventricles, are essential for driving CSF flow and ensuring the efficient removal of these toxic substances. Given the high morbidity and mortality associated with TBI and the lack of effective pharmacological interventions, there is a pressing need for novel therapies that can enhance the brain's natural clearance mechanisms to improve patient outcomes.
Current approaches to TBI management are largely limited to supportive care and surgical interventions aimed at controlling intracranial pressure or repairing structural damage. There are no approved pharmacological treatments that directly address the secondary injury processes, such as impaired waste clearance or BBB dysfunction, that contribute to poor neurological recovery. Existing therapies do not target the underlying mechanisms of neurotoxic metabolite accumulation, and as a result, patients often experience prolonged neurological deficits and increased risk of chronic neurodegeneration. Furthermore, while external ventricular drains (EVDs) are routinely used in severe TBI cases to manage CSF pressure, they are not leveraged to enhance CSF-mediated clearance of harmful substances. This gap in treatment highlights the limitations of current strategies and underscores the urgent need for innovative solutions that can actively promote brain repair and functional recovery after TBI.
Technology Description
This technology is a pharmacological treatment designed to improve outcomes after traumatic brain injury (TBI) by enhancing the brain’s natural waste clearance system. It works by stimulating the motility of ependymal cilia—tiny hair-like structures lining the brain’s ventricles—which increases the flow of cerebrospinal fluid (CSF) and accelerates the removal of neurotoxic metabolites that accumulate after injury. Key compounds such as clindamycin and terbutaline serve as cilia activators, with intraventricular administration via external ventricular drains (EVDs) being the preferred delivery method for severe cases, though oral and intravenous routes are also under consideration. Preclinical studies in animal models have demonstrated that this approach boosts cilia activity, reduces blood-brain barrier (BBB) disruption, and leads to faster neurological recovery, as evidenced by improved consciousness and behavioral outcomes.
What differentiates this technology is its novel mechanism of action—direct pharmacological modulation of ependymal cilia motility to enhance CSF-mediated clearance of harmful substances—addressing a critical gap in TBI treatment where no effective pharmacological therapies currently exist. Unlike conventional approaches that focus on supportive care or surgical intervention, this solution leverages FDA-approved drugs with established safety profiles, enabling rapid clinical translation. The use of EVDs for drug delivery integrates seamlessly with standard care for severe TBI, minimizing additional invasiveness. Furthermore, the technology’s foundation in recent advances in glymphatic system biology, combined with robust preclinical validation, positions it as a paradigm shift in neurocritical care. Its potential for adaptation to oral formulations could expand its applicability to a broader range of CNS injuries, offering a scalable and transformative therapeutic option for millions of patients.
Benefits
- Enhances brain's natural clearance of neurotoxic metabolites by stimulating ependymal cilia motility
- Increases cerebrospinal fluid (CSF) flow, accelerating removal of harmful substances after traumatic brain injury
- Promotes restoration of the blood-brain barrier, reducing secondary brain damage
- Improves neurological recovery and speeds functional recovery post-injury
- Utilizes repurposed FDA-approved drugs with established safety profiles for rapid clinical translation
- Allows multiple administration routes, including intraventricular delivery via existing external ventricular drains
- Complements current surgical and supportive treatments for traumatic brain injury
- Potentially applicable to a broad range of central nervous system injuries involving toxic metabolite accumulation
Commercial Applications
- Acute traumatic brain injury treatment
- Enhancing recovery after neurosurgery
- Adjunct therapy for CNS infections
- Reducing neurotoxic metabolite buildup
Additional Information
This pharmacological treatment for traumatic brain injury enhances the brain's natural clearance mechanisms. It stimulates ependymal cilia motility, increasing cerebrospinal fluid flux to accelerate neurotoxic metabolite removal. This promotes blood-brain barrier restoration and improves neurological recovery. Compounds like clindamycin and terbutaline, administered intraventricularly or via other routes, serve as cilia activators.
Patent PCT/US2025/056123 filed 11/19/25
